Get the Stockscreener App
59.17
2.92%
-1.78
Pre-market:
59.50
0.33
+0.56%
Bright Minds Biosciences Inc stock is traded at $59.17, with a volume of 938.23K.
It is down -2.92% in the last 24 hours and down -23.62% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$60.95
Open:
$61.86
24h Volume:
938.23K
Relative Volume:
3.52
Market Cap:
$580.58M
Revenue:
-
Net Income/Loss:
$-19.80M
P/E Ratio:
-24.22
EPS:
-2.4426
Net Cash Flow:
$-14.56M
1W Performance:
-9.36%
1M Performance:
-23.62%
6M Performance:
-30.93%
1Y Performance:
+114.54%
1-Day Range:
$59.00
$62.55
1-Week Range:
$59.00
$69.97
52-Week Range:
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
59.17 | 580.58M | 0 | -19.80M | -14.56M | -2.4426 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences (DRUG) Slides 1% as Buyers and Sellers Battle Near Critical LevelsBull Flag - newsline.com
Behavioral Patterns of DRUG and Institutional Flows - Stock Traders Daily
Bright Minds Biosciences (DRUG) Surges 3.86% as Shares Test Key Resistance ZoneMomentum Trade - newsline.com
News Releases for Bright Minds Biosciences Inc. - The Canadian Securities Exchange (CSE)
Bright Minds Biosciences Sets March 31, 2026 AGM, Files Meeting Materials on Form 6-K - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) details 2026 AGM, board nominees and auditor - Stock Titan
H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data - Investing.com UK
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting - TipRanks
Bright Minds (DRUG) outlines 2026 AGM in Vancouver with key record dates - Stock Titan
H.C. Wainwright Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $145 - Moomoo
H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data By Investing.com - Investing.com South Africa
DRUG Reiterated by HC Wainwright & Co. -- Price Target Maintained at $145 - GuruFocus
(DRUG) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) grants 109,000 options and sets June 3 Jefferies talk - Stock Titan
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference - Weekly Voice
Bright Minds, a biotech targeting epilepsy, to speak at Jefferies health event - Stock Titan
Bright Minds Biosciences (DRUG) Edges Higher Amid Consolidation Near Key Support LevelLiquidity Order Flow - newsline.com
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - AOL.com
B Group Discloses New Position in Bright Minds Biosciences - HarianBasis.co
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - The Motley Fool
Bright Minds Biosciences Stock Jumps After $220 Piper Sandler Call—What DRUG Traders Are Watching - Bez Kabli
Piper Sandler raises Bright Minds stock price target on program progress - Investing.com UK
Piper Sandler Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Raises Target Price to $220 - Moomoo
Piper Sandler raises Bright Minds stock price target on program progress By Investing.com - Investing.com South Africa
Bright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing - TipRanks
[6-K] BRIGHT MINDS BIOSCIENCES INC. Current Report (Foreign Issuer) | DRUG SEC FilingForm 6-K - Stock Titan
Vestal Point (DRUG) and Ryan Wilder report 492,319 shares, 5% stake - Stock Titan
Janus Henderson (DRUG) discloses 1.28M shares, 13.1% stake - Stock Titan
Janus Henderson Group (DRUG) discloses 1.28M shares, 13.1% stake - Stock Titan
Bright Minds Biosciences Inc. (DRUG) Eps Diluted (TTM) - Zacks Investment Research
Vivo entities disclose 504,645 shares in Bright Minds Biosciences (DRUG) - Stock Titan
TradingKey - TradingKey
Bright Minds Biosciences Inc expected to post a loss of C$1.19 a shareEarnings Preview - TradingView
Bright Minds Biosciences (DRUG) to Release Earnings on Friday - MarketBeat
Trading Systems Reacting to (DRUG) Volatility - Stock Traders Daily
This Insider Has Just Sold Shares In Bright Minds Biosciences - simplywall.st
DRUG SEC FilingsBright Minds Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cormorant sells $9.78m in Bright Minds Biosciences stock - Investing.com UK
Cormorant sells $9.78m in Bright Minds Biosciences stock By Investing.com - Investing.com Australia
[SCHEDULE 13G/A] BRIGHT MINDS BIOSCIENCES INC. Amended Passive Investment Disclosure - Stock Titan
Insider Selling: Bright Minds Biosciences (NASDAQ:DRUG) Major Shareholder Sells 109,331 Shares of Stock - MarketBeat
Bright Minds Biosciences(DRUG.US) Insider Sells US$9.79 Million in Common Stock - Moomoo
Bright Minds Biosciences (DRUG) holder sells 109,331 shares in open market - Stock Titan
Bright Minds announces ATM offering up to $100 million - MSN
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):